MarketPulse — Real-Time Financial News & Market Analysis

Berkshire Hathaway's new CEO Greg Abel confirms no immediate dividend, but signals the board annually reviews the policy and could consider dividends if capital returns deteriorate.

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.

Global Indemnity Group declares $0.35 quarterly distribution per share payable March 30, 2026, reflecting confidence in its diversified P&C insurance portfolio performance.

Katahdin Bankshares Corp. ($KTHN) releases 2025 annual report, maintaining $1.12B in assets across 16 Maine locations.

Enphase Energy faces class action lawsuit over alleged misstatements on inventory management and tax credit impacts. Lead plaintiff deadline: April 20, 2026.

Averin Capital SPAC closes partial overallotment, raising $33.86M additional proceeds for total IPO capital of $283.86M.

MAIA Biotech secures $30M funding and FDA Fast Track designation for ateganosine cancer therapy, with Phase 2 data showing 17.8-month median survival.

Pixalate launches daily-updated blocklist tracking 7.8M apps removed from Google Play and Apple App Store, helping ad tech platforms prevent fraud and privacy risks.

uniQure faces shareholder lawsuit alleging false statements on FDA approval and study design. Lead plaintiff deadline: April 13, 2026.

Boeing shares fell 2.30% as 20,000+ flights grounded and 1M+ travelers stranded amid U.S.-Israel strikes on Iran and Mexico violence, pressuring airlines and aircraft demand.

BMY and MDT offer attractive dividend yields and growth potential, with BMY at 4% yield and MDT boasting 48 years of consecutive increases.

UPS stock down 8% over past year amid revenue headwinds and margin pressure, but analyst maintains buy rating citing H2 2026 recovery as unprofitable Amazon work exits.

Alphabet stock doubled from 2025 lows, but whether it's cheap or expensive depends on AI execution and earning growth sustainability at current valuations.

Palantir surged 547% over five years but faces valuation scrutiny at 110x forward earnings. Strong Q4 growth and AI demand offer upside, though 26% recent pullback signals volatility ahead.

The Trade Desk shares fell 21.5% in February after reporting 14% Q4 revenue growth and guiding to just 10% Q1 2026 growth, pressured by competition and AI uncertainty. Insider buying and OpenAI partnership reports have sparked a partial recovery.

Tesla shifts focus to robotaxis and humanoid robots amid declining vehicle sales and earnings. Massive upside potential offset by execution risks and stretched valuation.

Robbins LLP filed class action against $KD over alleged financial statement misstatements and internal control failures. Stock plunged 55% after SEC investigation disclosure.

Block & Leviton investigates $DSGR for securities fraud after 25% stock collapse reveals inconsistent tariff management statements between November and March.

Tevogen Bio signs Letter of Intent to acquire Apozeal Pharmaceutical, gaining 11 FDA-approved generics and pipeline assets to expand domestic manufacturing strategy.

Tevogen Bio ($TVGN) targets Apozeal Pharmaceutical acquisition to gain 11 FDA-approved generics and strengthen domestic drug manufacturing.